FreeCME

Patient, Provider, and Caregiver Connection™: Collaborative Approaches to Chronic Kidney Disease Management in T2DM

CME: 1.5

Target Audience

This educational activity is directed toward nephrologists, cardiologists, primary care clinicians, nurse practitioners, and physician assistants, and other health care professionals involved in the management of patients with CKD.

Program Overview

This video-based program is designed for health care professionals to explore the available treatments for diabetic kidney disease (DKD) through a unique perspective, putting the patient’s voice front and center. A patient will lend their expertise to this program by sharing their journey living with DKD. This online activity focuses on the complex disease pathophysiology of DKD, the diseases and complications directly related to DKD, and the efficacy and safety of therapies recommended for treating DKD.

Diabetic kidney disease (DKD) is a disease multiplier that increases the risk of stroke and cardiac and vascular disease. Patients with DKD have a high risk of renal and diabetes complications, including diabetic retinopathy, diabetic foot, anemia, metabolic bone disease, fractures, infection, and neuropathy. Not surprisingly, this burden of complications and comorbidities translates to poor quality of life and substantially higher healthcare resource utilization and costs. Effective treatment for DKD is a key unmet need because, although advances in diabetes care have substantially reduced the incidence of most diabetes complications, efforts to reduce progression to end-stage renal disease (ESRD) have stubbornly lagged behind others. There are several classes of glucose-lowering drugs that have shown beneficial renal effects in patients with DKD. These include sodium-glucose cotransporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and nonsteroidal mineralocorticoid receptor antagonists (MRAs).

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe recommended diagnostic practices for CKD in patients with type 2 diabetes mellitus (T2DM)
  • Evaluate the efficacy and safety profiles of available antihyperglycemic agents and their cardiovascular and renal benefits in patients with T2DM
  • Recognize the complex pathophysiology of CKD and emerging approaches to intervene in disease progression

Post a comment to this article